259 related articles for article (PubMed ID: 36422853)
1. Real-world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease.
Folkerts K; Millier A; Smela B; Olewinska E; Schmedt N; Mernagh P; Kovesdy CP
J Nephrol; 2023 May; 36(4):1135-1167. PubMed ID: 36422853
[TBL] [Abstract][Full Text] [Related]
2. Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study.
Blankenburg M; Fett AK; Eisenring S; Haas G; Gay A
BMC Nephrol; 2019 May; 20(1):171. PubMed ID: 31096928
[TBL] [Abstract][Full Text] [Related]
3. Non-steroidal mineralocorticoid receptor antagonists and cardiorenal outcomes in chronic kidney disease.
Lo KB; Rangaswami J; Vaduganathan M
Nephrol Dial Transplant; 2023 Mar; 38(4):845-854. PubMed ID: 36472546
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
Lerma E; White WB; Bakris G
Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular and Renal Benefit of Novel Non-steroidal Mineralocorticoid Antagonists in Patients with Diabetes.
Kintscher U
Curr Cardiol Rep; 2023 Dec; 25(12):1859-1864. PubMed ID: 37991625
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
Marzolla V; Infante M; Armani A; Rizzo M; Caprio M
Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659
[TBL] [Abstract][Full Text] [Related]
7. Effects of Mineralocorticoid Receptor Antagonists for Chronic Kidney Disease: A Systemic Review and Meta-Analysis.
Yuan CY; Gao YC; Lin Y; Liu L; Shen XG; Zou WL; Wang MM; Shen QQ; Shao LN; Liu YM; Zhang JW; Pan ZH; Zhu Y; Yu JT; Yu XG; Zhu B
Am J Nephrol; 2024; 55(1):1-17. PubMed ID: 37793348
[TBL] [Abstract][Full Text] [Related]
8. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
Pandey AK; Bhatt DL; Cosentino F; Marx N; Rotstein O; Pitt B; Pandey A; Butler J; Verma S
Eur Heart J; 2022 Aug; 43(31):2931-2945. PubMed ID: 35713973
[TBL] [Abstract][Full Text] [Related]
9. Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease.
Mavrakanas TA; Giannetti N; Sapir-Pichhadze R; Alam A
Cardiorenal Med; 2020; 10(1):32-41. PubMed ID: 31665724
[TBL] [Abstract][Full Text] [Related]
10. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
Yang S; Zhao L; Mi Y; He W
Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists for renal outcomes: A systematic review and meta-analysis.
Chen Q; Liang Y; Yan J; Du Y; Li M; Chen Z; Zhou J
Diabetes Res Clin Pract; 2023 Jan; 195():110210. PubMed ID: 36509181
[TBL] [Abstract][Full Text] [Related]
12. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
[TBL] [Abstract][Full Text] [Related]
13. Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis.
Lu R; Zhang Y; Zhu X; Fan Z; Zhu S; Cui M; Zhang Y; Tang F
Int Urol Nephrol; 2016 Sep; 48(9):1499-509. PubMed ID: 27193436
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.
Lv R; Xu L; Che L; Liu S; Wang Y; Dong B
Front Endocrinol (Lausanne); 2023; 14():1125693. PubMed ID: 36860374
[TBL] [Abstract][Full Text] [Related]
15. Mineralocorticoid receptor antagonists in patients with chronic kidney disease.
Cosimato C; Agoritsas T; Mavrakanas TA
Pharmacol Ther; 2021 Mar; 219():107701. PubMed ID: 33027644
[TBL] [Abstract][Full Text] [Related]
16. Steroidal MRA Across the Spectrum of Renal Function: A Pooled Analysis of RCTs.
Ferreira JP; Pitt B; McMurray JJV; Pocock SJ; Solomon SD; Pfeffer MA; Zannad F; Rossignol P
JACC Heart Fail; 2022 Nov; 10(11):842-850. PubMed ID: 36328653
[TBL] [Abstract][Full Text] [Related]
17. The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature.
Georgianos PI; Agarwal R
Am J Hypertens; 2023 Feb; 36(3):135-143. PubMed ID: 36331811
[TBL] [Abstract][Full Text] [Related]
18. Mineralocorticoid receptor antagonists in heart failure patients with chronic kidney disease: why, when, and how?
Kassem H; Chatila K
Curr Opin Nephrol Hypertens; 2020 Mar; 29(2):258-263. PubMed ID: 31833939
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
[TBL] [Abstract][Full Text] [Related]
20. [Antifibrotic renal role of mineralcorticoid receptor antagonists].
Ocello A; La Rosa S; Fiorini F; Randone S; Maccarrone R; Battaglia G; Granata A
G Ital Nefrol; 2019 Jul; 36(4):. PubMed ID: 31373464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
